Medical tests

One Drop Announces Blood Glucose Predictive Capability for People Using Continuous Glucose Monitors

Monday, November 18, 2019 - 1:00pm

"One Drop's predictive model offers the most accurate blood glucose forecasts based on real-world data that have been published to date.

Key Points: 
  • "One Drop's predictive model offers the most accurate blood glucose forecasts based on real-world data that have been published to date.
  • Using more than 10 million hours of CGM data from One Drop users, the model accurately predicted blood glucose levels within 30 mg/dL of the CGM-measured values up to 120 minutes in advance.
  • Earlier this year, One Drop expanded its AI-powered Predictive Insights to include 8-hour blood glucose forecasts for One Drop mobile app users with type 2 diabetes, and each forecast is paired with a behavioral recommendation to help keep blood glucose in range.
  • One Drop is the only provider of blood glucose forecasts for people with type 2 diabetes.

Takeaways from AMP 2019 in Baltimore: Users of Bionano’s Saphyr System Presented Results from Multiple Studies Demonstrating the System’s Utility for a Variety of Disease Indications

Tuesday, November 12, 2019 - 1:00pm

Focusing on molecular diagnostics, quality health care through excellence in clinical molecular testing is at the core of AMP.

Key Points: 
  • Focusing on molecular diagnostics, quality health care through excellence in clinical molecular testing is at the core of AMP.
  • The association organizes an annual meeting to further its vision of providing global expertise in molecular testing that drives patient care.
  • Saphyr users chose AMP as a venue to present updates to their findings using the Saphyr System for a variety of disease indications:
    Moffitt Cancer Center.
  • Ascites is the abnormal build-up of fluid in the abdomen, which can be caused by an inflammatory reaction to metastatic cancer cells.

Confirm BioSciences Unveils HealthConfirm® At-Home Testing Kits, For a Healthier You

Tuesday, November 12, 2019 - 1:01pm

Each kit comes with instructions for use, including how to properly collect the non-invasive saliva, dried urine or blood spot samples required for testing.

Key Points: 
  • Each kit comes with instructions for use, including how to properly collect the non-invasive saliva, dried urine or blood spot samples required for testing.
  • "HealthConfirm at-home testing kits allow people to take part in their wellness in a convenient, productive and meaningful way."
  • Additional HealthConfirm testing kits will soon be available to assist in weight management and biometrics testing.
  • Confirm BioSciences is a leading provider of high-quality, comprehensive screening tools and solutions across the full spectrum of health and wellness.

Global Molecular Diagnostics Market Report 2019 with Historical Data from 2016 and Forecasts to 2025 - ResearchAndMarkets.com

Tuesday, November 12, 2019 - 10:35am

The report covers a forecast and an analysis of the molecular diagnostics market on a global and regional level.

Key Points: 
  • The report covers a forecast and an analysis of the molecular diagnostics market on a global and regional level.
  • The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Billion).
  • Additionally, the report includes the study of opportunities available in the molecular diagnostics market on a global level.
  • Some major players of the global molecular diagnostics market are Becton Dickinson, Abbott Laboratories, Roche Diagnostics, Novartis, Johnson and Johnson, bioMerieux, Bio-Rad Laboratories, Qiagen NV, Siemens Healthcare, Danaher Corporation, and Hologic.

Castle Biosciences Reports Third Quarter 2019 Results

Monday, November 11, 2019 - 9:05pm

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced its financial results for the third quarter and nine months ended September 30, 2019.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced its financial results for the third quarter and nine months ended September 30, 2019.
  • Delivered 4,126 DecisionDx-Melanoma test reports in the 2019 third quarter, compared to 3,136 reports during the third quarter of 2018, representing growth of 32%.
  • Delivered 356 DecisionDx-UM test reports in the 2019 third quarter, compared to 324 reports during the third quarter of 2018, representing growth of 10%.
  • Castle Biosciences will hold a conference call on Monday, November 11, 2019, at 4:30 p.m. Eastern time to discuss its third quarter 2019 results and provide a corporate update.

Myriad Genetics to Present at the 2019 Stephens Nashville Investment Conference

Thursday, November 7, 2019 - 9:05pm

SALT LAKE CITY, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that Bryan Riggsbee, CFO, is scheduled to present at the Stephens Nashville Investment Conference at 12:15 p.m. EST on November 13, 2019, in Nashville.

Key Points: 
  • SALT LAKE CITY, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that Bryan Riggsbee, CFO, is scheduled to present at the Stephens Nashville Investment Conference at 12:15 p.m. EST on November 13, 2019, in Nashville.
  • Myriad Genetics, Inc., is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.
  • For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com .
  • Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore Prolaris, ForeSight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries.

Genomind Bolsters Medicare Reimbursement Initiatives, Obtaining Z-Codes for Genomind Professional PGx Express

Thursday, November 7, 2019 - 1:05pm

Genomind Professional PGx Express is the most advanced and comprehensive genetic testing service available to guide mental health medication management.

Key Points: 
  • Genomind Professional PGx Express is the most advanced and comprehensive genetic testing service available to guide mental health medication management.
  • This process identifies and establishes coverage and reimbursement policies for molecular diagnostic tests, which would include Genomind Professional PGx Express, as part of Medicares Local Coverage Determination (LCD) process.
  • Genomind Professional PGx Express available by prescription only is the most advanced and comprehensive genetic testing service available to guide mental health medication management.
  • Genomind Professional PGx Express analyzes up to 24 genes, identifying patient-specific genetic markers that can better inform mental health treatment decisions.

Cell Analysis Markets, 2024 - Focus on by Product [Microscope, Spectrophotometers, Flow cytometry (Software, Accessories)], Process (Cell Viability, Cell Proliferation, Signal Transduction) - ResearchAndMarkets.com

Thursday, November 7, 2019 - 12:00pm

The "Cell Analysis Market by Product [Microscope, Spectrophotometers, Flow cytometry (Software, Accessories)], Process (Cell Viability, Cell Proliferation, Signal Transduction), End User (Pharma, Research, Biotechnology Companies) - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Analysis Market by Product [Microscope, Spectrophotometers, Flow cytometry (Software, Accessories)], Process (Cell Viability, Cell Proliferation, Signal Transduction), End User (Pharma, Research, Biotechnology Companies) - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.
  • The cell analysis market is projected to reach USD 22.75 billion by 2024 from USD 16.05 billion in 2019, at a CAGR of 7.2%.
  • Geographically, the cell analysis market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.
  • In 2018, North America accounted for the largest share of the cell analysis market.

Global Wireless ECG Devices Market Growth, Trends & Forecasts (2019-2024) - ResearchAndMarkets.com

Wednesday, November 6, 2019 - 6:58pm

The "Wireless ECG Devices Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Wireless ECG Devices Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
  • The major factors for the growth of the wireless ECG devices market include the growing geriatric population and increasing incidence of cardiovascular diseases, declining cost of wireless technologies, technological advancements in remote monitoring technologies, and policies favoring monitoring devices.
  • The wireless ECG cardiac monitors developed by a UK-based medical services startup, Isansys, help to manufacture low-cost continuous ECG heart monitoring devices.
  • The wireless ECG devices market is a moderately consolidated market, owing to the presence of a few major players and small players in the market.

FDA Grants De Novo Designation for Vela Diagnostics’ Next Generation Sequencing HIV-1 Genotyping Assay

Wednesday, November 6, 2019 - 1:00pm

It is the first and only HIV-1 genotyping NGS assay currently available on the market to receive marketing authorization from the FDA.

Key Points: 
  • It is the first and only HIV-1 genotyping NGS assay currently available on the market to receive marketing authorization from the FDA.
  • The granting of the De Novo designation of our NGS assay by the U.S. FDA is a major milestone in HIV diagnostics.
  • In addition to receiving the FDA De Novo designation, the current configuration of the assay is pending review for the CE mark and from the HSA.
  • Vela Diagnostics is a leading provider of an automated IVD NextGeneration Sequencing (NGS) workflow in the global diagnostics market.